Form 4 for EW Edwards Lifesciences
Accepted 2025-03-10 00:00:00 ET · period of report 2025-03-10 · accession 0001225208-25-003195 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-10 | 2025-03-10 | EW | Zovighian Bernard J | CEO, Dir | G - Gift | $0.00 | -1,299 | 65.2K | -2% | $0 |
| D | 2025-03-10 | 2025-03-10 | EW | Zovighian Bernard J | CEO, Dir | S - Sale+OE | $69.51 | -6,164 | 59.1K | -9% | -$428.5K |
| DI | 2025-03-10 | 2025-03-10 | EW | Zovighian Bernard J | CEO, Dir | G - Gift | $0.00 | +1,299 | 10.4K | +14% | $0 |
| D | 2025-03-10 | 2025-03-10 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $45.28 | +7,463 | 66.5K | +13% | +$337.9K |
| D | 2025-03-10 | 2025-03-10 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $0.00 | -7,463 | 7,462 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-10 | G | D | 1,299 | $0.00 | 65,246.90 | D | — | — | |
| 2 | Common | Common Stock | 2025-03-10 | S | D | 6,164 | $69.51 | 59,082.90 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $69.41 to $69.64 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2025-03-10 | G | A | 1,299 | $0.00 | 10,436 | I | — | — | |
| 4 | Common | Common Stock | 2025-03-10 | M | A | 7,463 | $45.28 | 66,545.90 | D By Trust | — | — | |
| 5 | Derivative | Employee Stock Option (Right to Acquire) | 2025-03-10 | M | D | 7,463 | $0.00 | 7,462 | D | $45.28 · — to 2025-05-16 | 7,463 Common Stock | (F4) These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one yearafter the grant date in four equal annual installments. |